Drug Profile
F 17752
Alternative Names: F17752Latest Information Update: 17 Oct 2018
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 17 Oct 2018 Discontinued - Phase-I/II for Solid tumours (In the elderly, In adults) in France (PO)
- 30 Sep 2013 Phase-I/II clinical trials in Solid tumours (In adults, In the elderly) in France (PO)